NEOsphere Biotechnologies GmbH

NEOsphere Biotechnologies combines world-class mass spectrometry with expert data analysis to systematically create broad pipelines of novel degrader targets at scale and advance our partners’ targeted protein degradation (TPD) drug discovery programs at all stages.

Our unique target and E3 ligase-agnostic deep proteomic screening platform unbiasedly screens entire degrader libraries at high throughput. With unmatched proteome coverage, sensitivity, precision, and rapid turnaround times, we systematically unlock the previously undruggable target space. Our platform characterizes all types of degraders and identifies molecules acting through new E3 ligases and emerging TPD mechanisms. Potential degrader targets and degrader-induced modifications are confirmed through global ubiquitinomics, reaching an unparalleled depth of 50,000 ubiquitination sites.

Our proprietary data analysis suite for interactive and user-friendly data analysis makes even large proteomics data instantly accessible for informed drug discovery decision making, SAR optimization, target identification, and library expansion.